Coloplast pares back China operations as market recovery remains elusive

What happened

Coloplast cut 80 jobs in its China commercial operations and does not expect that business to stabilize until 2027/28. China is about 4% of group sales and has hurt its ostomy care division, where local competition and weak consumer confidence reduce demand.

Confirmed

Global impact / market context

Fewer Chinese staff and lower inventories reduce Coloplast's local costs and unsold stock, but the ostomy business loses sales to local rivals. Investors should expect a slower China recovery, with the company relying on a 500 million Danish crown savings program to support profit.

Analyst inference

China's medical equipment market is shifting toward local brands, as Cofoe Medical Technology says it took share from overseas brands. For Coloplast, this means weaker pricing power in a market where patients pay for ostomy bags themselves, making demand sensitive to household confidence.

Analyst inference

What to watch

1. Coloplast expects no China stabilization until 2027/28, so watch whether ostomy care sales and the roughly 4% China share of group sales keep shrinking before then. Confirmed
2. The company aims to free up 500 million Danish crowns through organizational changes, US Biologics adjustments and procurement savings; watch whether these savings offset China weakness. Proposed
3. Watch Cofoe Medical Technology's local market share gains and whether Coloplast's Zhuhai plant, with 750 staff, stays unaffected while commercial operations shrink. Analyst inference

Evidence

• Original source link unavailable